Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Alzheimer's disease (AD) pathogenesis involves neuronal loss and neuritic dystrophy.
• Amyloid beta peptide (A beta) is a known activator of the classical complement pathway.
• The aggregation state of A beta is increasingly recognized as critical in AD progression.

Purpose of the Study:

• To investigate whether the aggregation state of A beta influences its ability to activate the classical complement pathway.
• To correlate specific A beta aggregation states with complement activation markers.

Main Methods:

• Thioflavin T fluorometry to assess A beta aggregation.
• Electron microscopy for visualizing A beta fibril formation.
• Staining with Congo red and thioflavine S to confirm aggregation.
• Measurement of activated complement fragments C4 and C3.

Main Results:

• A precise correlation was observed between the fibrillar aggregation state of A beta and the induction of activated complement fragments C4 and C3.
• Fibrillar A beta, but not diffuse forms, significantly activated the classical complement pathway.
• Thioflavin T fluorometry, electron microscopy, and specific stains confirmed the fibrillar state.

Conclusions:

• The fibrillar aggregation state of A beta is a key determinant of its ability to activate the classical complement pathway.
• Complement activation by fibrillar A beta may contribute to complement-dependent neuronal injury in Alzheimer's disease brains.
• These findings highlight a mechanism linking A beta pathology to neuroinflammation and neuronal damage in AD.